KBY Biotech Indexv0.0.34
Search
← Pipeline|DSG-6263

DSG-6263

Phase 1/2
By Design Ther
Source: Trial-derived·Trials: 2
Modality
mRNA
MOA
RAS(ON)i
Target
MDM2
Pathway
Neuroinflam
Breast Ca
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
Jun 2019
→ Dec 2028
Phase 1Current
NCT07050944
803 pts·Breast Ca
2019-06→TBD·Not yet recruiting
NCT08704664
2,848 pts·Breast Ca
2022-05→2028-12·Recruiting
3,651 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-152.7y awayPh2 Data· Breast Ca
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2028-12-15 · 2.7y away
Breast Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT07050944Phase 1/2Breast CaNot yet recr...803eGFR
NCT08704664Phase 1/2Breast CaRecruiting2848CR
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-6079Eli LillyPhase 2MDM2PRMT5i
LLY-3251Eli LillyPhase 2MDM2BiTE
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
GSK-7987GSKPhase 3MDM2PD-1i
AMG-2752AmgenPreclinicalMDM2WRNi
REG-3155RegeneronPhase 1/2MDM2PI3Ki
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
SRP-1135SareptaPhase 2/3MDM2PD-L1i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i